Ipilimumab
Mixed Mesodermal (Mullerian) Tumor
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Mixed Mesodermal (Mullerian) Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Blueprint Medicines Corporation | Phase 3 | BB |
Ifosfamide GOG Foundation | Phase 3 | B |
Dkn-01 Leap Therapeutics, Inc. | Phase 2 | B |
Nivolumab Instituto do Cancer do Estado de São Paulo | Phase 2 | CCC |
Pamiparib Australia New Zealand Gynaecological Oncology Group | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →